Kanaph Therapeutics
Developing next generation therapeutics for oncology and autoimmune diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$95—143m (Dealroom.co estimates Dec 2023.)
Company register number 6438701092
South Korea (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $2.0m | Angel | |
$6.0m | Series A | ||
$21.0m | Series B | ||
| N/A | $23.8m | Series B | |
| Total Funding | $52.8m | ||